Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib vs Gefitinib as First-line Treatment in EGFR-mutated NSCLC
NCT04248829Phase 3Completed
- Sponsor
- Yuhan
- Start
- Feb 2020
- Primary completion
- Jul 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Lazertinib + Gefitinib-matching placebo with Gefitinib + Lazertinib-matching placebo (2 arms). Primary endpoint: Progression-Free Survival up to 29 months. Started Feb 2020; status: completed.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04248829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04248829.